# ELM-1 (NCT02290951)

> Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies

No report yet. It can be ordered.

- Drugs tested: odronextamab
- Indication: previously treated CD20-positive B-cell malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02290951
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Regeneron Pharmaceuticals
- Conditions: Non-Hodgkin Lymphoma; Chronic Lymphocytic Leukemia
- Interventions: Odronextamab multiple dose levels; Odronextamab multiple dose levels
- Enrollment: 200
- Primary outcome: Safety/overall frequency of adverse events (AEs)
- Primary outcome: Safety/dose limiting toxicities (DLTs)
- Primary outcome: Antitumor activity as measured by the objective response rate (ORR)

## Indexed commentary on ELM-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 8
- YouTube: 7
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=elm-1-nct02290951

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02290951", "email": "<work email>"}; the inbox owner confirms by the emailed link.